


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199983</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-6536</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title>
                <ISOAbbreviation>Biol. Blood Marrow Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk factors for transplant-associated thrombotic microangiopathy following autologous hematopoietic cell transplantation in high-risk neuroblastoma.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1083-8791(19)30370-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2019.06.006</ELocationID>
            <Abstract>
                <AbstractText>High-risk neuroblastoma has a poor prognosis and research studies have shown that increasing the intensity of therapy improves outcomes. Autologous hematopoietic cell transplant (aHCT) as consolidation therapy confers a significant survival advantage but is accompanied by significant morbidity. Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication caused by endothelial injury that often leads to hemolytic anemia, microthrombotic platelet consumption, and renal injury. Here we investigated the incidence, potential risk-factors, and sequelae of TA-TMA in patients with high-risk neuroblastoma. We conducted a retrospective chart review of all patients (n=141) with neuroblastoma in our institutions who underwent aHCT from 2000-2017. Ten patients (7%) developed TA-TMA. The patients in the TA-TMA group were similar to the rest of the subjects in demographics, disease burden, prior therapies, renal function, and timing of transplant. The type of conditioning regimen was the only statistically significant pre-transplant variable (p&lt;0.001). Six of the 15 (40%) patients intended to receive tandem transplants (cyclophosphamide/thiotepa, then carboplatin/etoposide/melphalan (CEM)), four of the 68 (6%) patients who received conditioning with single CEM, and none of the 56 who received busulfan/melphalan were diagnosed with TA-TMA. Patients with TA-TMA were more likely to require ICU transfer, have a longer length of stay in the hospital, and experience a delay or change in their subsequent therapy. In our cohort overall, patients with a delay in therapy following transplant appeared to have a worse overall survival, although the difference was not statistically significant. Due to this high incidence and significant morbidity, we have implemented standardized screening for TA-TMA during and after transplant. We anticipate that screening will lead to earlier intervention and decreased severity of disease.</AbstractText>
                <CopyrightInformation>Copyright Â© 2019. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tolbert</LastName>
                    <ForeName>Vanessa P</ForeName>
                    <Initials>VP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dvorak</LastName>
                    <ForeName>Christopher C</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Golden</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Francisco Benioff Children's Hospital, Oakland, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vissa</LastName>
                    <ForeName>Madhav</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Francisco Benioff Children's Hospital, Oakland, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El-Haj</LastName>
                    <ForeName>Nura</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of California San Francisco Benioff Children's Hospital, Oakland, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perwad</LastName>
                    <ForeName>Farzana</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matthay</LastName>
                    <ForeName>Katherine K</ForeName>
                    <Initials>KK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vo</LastName>
                    <ForeName>Kieuhoa T</ForeName>
                    <Initials>KT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of California San Francisco School of Medicine and Benioff Children's Hospital, San Francisco, California. Electronic address: Kieuhoa.Vo@ucsf.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biol Blood Marrow Transplant</MedlineTA>
            <NlmUniqueID>9600628</NlmUniqueID>
            <ISSNLinking>1083-8791</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Autologous hematopoietic cell transplant</Keyword>
            <Keyword MajorTopicYN="N">Neuroblastoma</Keyword>
            <Keyword MajorTopicYN="N">Pediatrics</Keyword>
            <Keyword MajorTopicYN="N">Tandem transplant</Keyword>
            <Keyword MajorTopicYN="N">Transplant-associated thrombotic microangiopathy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199983</ArticleId>
            <ArticleId IdType="pii">S1083-8791(19)30370-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbmt.2019.06.006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

